Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study

Grinsztejn B, Torres TS, Hoagland B, Coutinho C, Silva MST, Leite IC, Cunha M, Derrico M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourão[...]

Diagnostics for Hemorrhagic Fever Viruses: Lassa Fever as an Example

Dhar B, Espinoza N, Farzani T, Baudi I, Nosamiefan D, Garcia CY, Allan-Blitz LT, Samani P, Happi C, Sabeti P. Diagnostics for Hemorrhagic Fever Viruses:[...]

Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis

Gu Y, Gebremariam T, Ibrahim BA, Harb K, Chan A, Ibrahim AS. Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis. J Fungi (Basel).[...]